Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 190Cyclophosphamide 123Azacitidine 112Cytarabine 108fludarabine 91Specimen Handling 74Biopsy 53Daunorubicin 42Methotrexate 41Dexamethasone 38Rituximab 34blinatumomab 32Vincristine 32Decitabine 31fludarabine phosphate 30Injections 28Granulocyte Colony-Stimulating Factor 28Whole-Body Irradiation 26Magnetic Resonance Spectroscopy 26obinutuzumab 25Idarubicin 25acalabrutinib 23Prednisone 23Mycophenolic Acid 23Melphalan 21Busulfan 21gilteritinib 19Mercaptopurine 19Doxorubicin 19ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × GRN163L peptide × Other hematologic neoplasm × Clear all
NCT07320235 2026-04-22

IMAGINE

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Oncology Group

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡